Galapagos and MorphoSys expand antibody alliance
Galapagos NV and MorphoSys AG announced that they have expanded their antibody alliance in bone & joint diseases. Based on the progress made so far, the partners have agreed to add another antibody target to the alliance, thereby increasing the total number of programs to four.
The alliance aims to discover and develop antibody therapeutics based on novel modes of action in bone & joint diseases, including rheumatoid arthritis, osteoporosis and osteoarthritis. As part of the initial agreement, three targets implicated in bone & joint diseases were selected for the collaboration. Antibodies with high specificity towards the first target have been generated and are now being tested in disease-specific in vitro and in vivo experiments. In parallel, Galapagos has applied its target discovery platform to identify additional targets for antibody development. Based on this, Galapagos and MorphoSys have now added a fourth antibody target to the alliance. The partners have prioritized the targets in order to maximize the value and IP position of the respective therapeutic antibody programs.
"This collaboration provides Galapagos with a platform to develop antibody drugs for our proprietary targets," said Onno van de Stolpe, Chief Executive Officer of Galapagos. "This, together with more than 40 R&D small molecule programs, solidifies our leading position in discovering innovative approaches to address diseases with unmet medical need."
"The expansion of our proprietary pipeline is a key value driver for our company. In 2010, we plan to add up to four new proprietary programs including both fully owned and co-development opportunities such as with Galapagos," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys. "Our alliance with Galapagos gives us access to novel disease-related target molecules which could build the basis for first-in-class antibody therapies in the future."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
ProtAffin AG granted patent in EU for CellJammer discovery technology - Novel technology enables development of a new class of biopharmaceuticals
CSIC researchers find the role of a protein in the regulation of synapse formation - The work raises the need for a balance between the Pinkman protein and the sHSPs proteins during the development of the nervous system for its correct formation
Affymetrix Selected to Genotype More Than 9,000 Framingham Heart Study Samples - SHARE Project to Help Identify Genetic Variants Associated With Heart, Lung, Blood and Sleep Disorders
New app calculates corona infection risk in rooms - Size of aerosol droplets that virus carriers release strongly influences infectivity
Northern_Norway_Pharmaceutical_Trust
Cell culture: The opportunities and the challenges - The promise of cell culture is accelerating demand, and emphasising the challenges, of this process
Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program
St_John_Ambulance_in_England_and_Wales
Harold_Ridley_(ophthalmologist)
Henry_Suter
